

Via UPS  
Return Receipt Requested

July 18, 2018  
Mr. Mukesh Dalal  
General Manager  
Alkem Laboratories Ltd.  
167 Mahatma Gandhi Udyog Nagar Road  
Daman, Daman And Diu, 396210, India

Dear Mr. Dalal:

The U.S. Food and Drug Administration (FDA) conducted an inspection at Alkem Laboratories Ltd, FEI 3006370524, located at 167 Mahatma Gandhi Udyog Nagar Road, Daman, Daman And Diu, India 396210, from March 19 to 27, 2018. FDA has determined that the inspection classification of this facility is "voluntary action indicated" ("VAI").<sup>1</sup> Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP).

A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time. Despite this facility inspection classification, FDA recommends that you address any observations noted on the Form FDA 483 issued at the conclusion of the inspection or otherwise conveyed to you following the inspection. If not corrected, the same or similar conditions could lead to a future inspection being classified as "official action indicated" ("OAI").


This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of VAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product- and application-specific facility assessment conducted by CDER's Office of Pharmaceutical Quality. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact LT Matthew Schnupp, PharmD via telephone at (240) 402-4284 or email at [matthew.schnupp@fda.hhs.gov](mailto:matthew.schnupp@fda.hhs.gov).

Sincerely,



Milind Ganjawala  
Acting Director  
Division of Drug Quality II (DDQII)  
Office of Manufacturing Quality (OMQ)

<sup>1</sup> See Inspection Classification Definitions, at <https://www.fda.gov/ICECI/Inspections/ucm223231.htm>.